WallStSmart

Bruker Corporation (BRKR)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 496% more annual revenue ($20.61B vs $3.46B). BSX leads profitability with a 17.3% profit margin vs -0.3%. BSX appears more attractively valued with a PEG of 0.57. BSX earns a higher WallStSmart Score of 76/100 (B+).

BRKR

Hold

35

out of 100

Grade: F

Growth: 4.7Profit: 3.5Value: 5.0Quality: 5.5
Piotroski: 3/9Altman Z: 1.71

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BRKRUndervalued (+4.9%)

Margin of Safety

+4.9%

Fair Value

$44.60

Current Price

$56.53

$11.93 discount

UndervaluedFair: $44.60Overvalued
BSXSignificantly Overvalued (-18.7%)

Margin of Safety

-18.7%

Fair Value

$37.36

Current Price

$44.33

$6.97 premium

UndervaluedFair: $37.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BRKR0 strengths · Avg: 0/10

No standout strengths identified

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$69.50B9/10

Large-cap with strong market position

PEG RatioValuation
0.578/10

Growing faster than its price suggests

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

Areas to Watch

BRKR4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.7%4/10

2.7% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BRKR

BRKR has a balanced fundamental profile.

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bear Case : BRKR

The primary concerns for BRKR are PEG Ratio, Revenue Growth, Altman Z-Score.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Key Dynamics to Monitor

BRKR profiles as a turnaround stock while BSX is a mature play — different risk/reward profiles.

BRKR carries more volatility with a beta of 1.30 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 35/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bruker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.

Visit Website →

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?